Sionna Therapeutics (SION) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Voting matters and shareholder proposals
Four class II directors are up for election to serve until the 2029 annual meeting or until a successor is duly elected and qualified, or earlier death, resignation, or removal.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is proposed.
Proxies are authorized to vote on any other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Director nominees include H. Edward Fleming, Jr., M.D., Marcella Kuhlman Ruddy, M.D., Peter A. Thompson, M.D., and Joanne Louise Viney, Ph.D.
Audit committee and external auditor matters
Deloitte & Touche LLP is recommended for ratification as the independent registered public accounting firm for the 2026 fiscal year.
Latest events from Sionna Therapeutics
- 2026 meeting to elect directors, ratify auditor, and highlight governance and compensation practices.SION
Proxy filing27 Apr 2026 - Advancing novel NBD1 stabilizers for CF, with pivotal data expected mid-2026 and strong cash runway.SION
Leerink Global Healthcare Conference 202610 Mar 2026 - NBD1 stabilizers aim to set a new efficacy bar in CF by targeting unmet needs beyond current therapies.SION
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Advancing NBD1 stabilizers for CF with strong clinical progress and cash runway into 2028.SION
Corporate presentation2 Mar 2026 - Advanced pipeline and strong cash position support operations into 2028; key data due mid-2026.SION
Q4 20252 Mar 2026 - NBD1 stabilizer programs target major CF mutations, with pivotal data expected mid-2026.SION
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026 - Advancing NBD1 stabilizers to transform CF care, with key data expected mid-2026.SION
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - NBD1 stabilizers show promise for CF, with pivotal trial results expected mid-2026.SION
Corporate presentation13 Jan 2026 - Advancing two NBD1 stabilizers in CF, aiming for superior efficacy over current therapies.SION
Cantor Global Healthcare Conference 20255 Jan 2026